

DATE: October 31st, 2025
 TO: All Sendero Health Plans Network Providers
 RE: New Preauthorization List effective 1/1/2026

Dear Sendero Physicians and Providers,

Sendero remains committed to balancing the administrative burden of preauthorization while ensuring Members receive clinically appropriate and cost-effective services. We continuously review and refine the list of services requiring preauthorization, including only those services where pre-review provides value in terms of member safety, clinical appropriateness, and responsible healthcare spending.

Below is a summary of the changes to the Sendero preauthorization list, **effective 1/1/2026**.

Summary of Changes to the Prior Authorization List

Effective January 1, 2026, Sendero has updated its preauthorization requirements as explained below. The full list of healthcare service codes requiring preauthorization is available at <https://senderohealth.com/preauthorizationsearch/>.

Updated Clinical Criteria for Medically Billed Drugs

Beginning January 1, 2026, Sendero has revised the clinical criteria for certain drugs billed under medical benefits to align with current clinical guidelines and best practices. The complete criteria are available to providers and members upon request. For reference, a list of affected HCPCS codes is provided below.

HCPCS	Drug Description	HCPCS	Drug Description
J3262, Q0249	Actemra (tocilizumab)	J2267	OmvoH (mirikizumab-mrzk)
Q5133	Tofidence (tocilizumab-anoh)	J3357, J3358	Stelara (ustekinumab)
J0717, J0718	Cimzia (certolizumab)	J3245	Ilumya (tildrakizumab-asmn)

Healthcare Services Added to the Preauthorization Requirement

Drugs administered in Office, Outpatient, or Home Setting			
HCPCS	Drug Description	HCPCS	Drug Description
Q5156	Avtozma (tocilizumab-anoh)	Q5098	Imuldosa (ustekinumab-srlf)
Q5135	Tyenne (tocilizumab-aazg)	Q9999	Otulfi (ustekinumab-aazg)
J0139	Humira (adalimumab)*	Q9996	Pyzchiva (ustekinumab-ttwe)
Q5145	Abrilada (adalimumab-afzb)*	Q9997	Pyzchiva (ustekinumab-ttwe)
Q5143	Cyltezo (adalimumab-adbm)	Q9998	Selarsdi (ustekinumab-aekn)
Q5140	Hulio (adalimumab-fkip)	Q5099	Stegeyma (ustekinumab-stba)
Q5144	Idacio (adalimumab-aacf)*	Q5137	Wezlana (ustekinumab-auub)
Q5142	Simlandi (adalimumab-ryvk)	Q5138	Wezlana (ustekinumab-auub)
Q5144	Yuflyma (adalimumab-aaty)	Q5100	Yesintek (ustekinumab-kfce)

**Drugs already included in preauthorization requirement but with new or reassigned HCPCS codes.*

Additional Notes:

The **Quick Reference Guide** is divided into two sections:

- Health care services that require **notification** to Sendero
- Health care services that require **preauthorization**

All covered services must be **medically necessary**, regardless of whether preauthorization is required and may be subject to **retrospective review** to assess medical necessity.

Sendero provides an **interactive healthcare service code lookup tool** to identify specific codes requiring preauthorization. This tool is available at <https://senderohealth.com/preauthorizationsearch/> and can also be accessed via the **Preauthorizations** tab at www.senderohealth.com.